Skip to main content
. 2020 Jun 20;43(10):999–1009. doi: 10.1007/s40264-020-00957-w

Table 5.

Top assessed adverse events in the second phase of the study (total number of assessed signals = 61)

Adverse event (MedDRA Preferred Term) Preliminary assessed signals (%)
Overdose 3 (4.9)
Anaemia 2 (3.3)
Anaphylactic reaction 2 (3.3)
Angioedema 2 (3.3)
Death 2 (3.3)
Loss of consciousness 2 (3.3)
Tachycardia 2 (3.3)